Abiraterone Acetate Administration Guidelines

Introduction to Abiraterone Acetate Administration

The American Society of Clinical Oncology (ASCO) guidelines explicitly state that the standard regimen is abiraterone 1,000 mg on an empty stomach, and do not support alternative dosing with food in routine practice 1, 2
Food dramatically increases abiraterone absorption, but this creates problems rather than benefits due to unpredictable variability in bioavailability when taken with food, making dosing unreliable 1, 2

The National Comprehensive Cancer Network (NCCN) guidelines mention that 250 mg/day with a low-fat breakfast can be given as an alternative to 1,000 mg fasted, but with important caveats, including cost consideration, critical warning about food impacting absorption unpredictably, and the need for monitoring for excess toxicity 3
A micronized formulation was designed to overcome food-related effects, with a dose of 500 mg daily with methylprednisolone 4 mg twice daily, and is FDA-approved only for metastatic castration-resistant prostate cancer 1, 2, 3

Monthly monitoring is essential, including liver function tests (ALT, AST, bilirubin), electrolytes (serum potassium and phosphate), blood pressure, and cardiac assessment, especially in patients with pre-existing cardiovascular disease 5
The ASCO guidelines do not support use of the micronized formulation in the non-castrate setting, and emphasize that the two formulations have different indications and dosing, and are not interchangeable 1, 2

If a patient cannot comply with fasting, consider switching to enzalutamide 160 mg daily, which does not require fasting or concurrent steroids 1, 2, 4
Only consider food-based dosing if standard dosing is financially prohibitive, the patient has demonstrated inability to take medication fasted, close monitoring for toxicity is feasible, and the patient understands this is off-label use 3, 5